Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
Neurotech International (NTI) has flagged to its shareholders that the FDA hasn't granted its product NTI164 orphan drug status.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
LN3 | Note Deed Poll | 25/07/24 | ||
LN3 | Master Trust Deed | 25/07/24 | ||
LN3 | Master Security Trust Deed | 25/07/24 | ||
LN3 | Issue Supplement | 25/07/24 | ||
LN3 | General Security Deed | 25/07/24 | ||
LN3 | Information Memorandum | 25/07/24 | ||
LN3 | Appendix 1B and Information Form and Checklist | 25/07/24 | ||
LN3 | Admission and Commencement as an ASX Debt Listing | 25/07/24 | ||